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Abstract 1 
Genome-wide association studies (GWAS) show that many common alleles confer 2 
risk for developing Alzheimer’s disease (AD). These risk loci may contribute to MRI 3 
alterations in young individuals, preceding the clinical manifestations of AD. Prior 4 
evidence identifies vascular dysregulation as the earliest marker of disease 5 
progression. However, it remains unclear whether cerebrovascular function 6 
(measured via grey-matter cerebral blood flow (gmCBF)) is altered in young 7 
individuals with increased AD genetic risk. We establish relationships between 8 
gmCBF with APOE and AD polygenic risk score in a young cohort (N=75; aged: 19-9 
32). Genetic risk was assessed via a) possessing at least one copy of the APOE ɛ4 10 
allele and b) a polygenic risk score (AD-PRS) estimated from AD-GWAS. We 11 
observed a reduction in gmCBF in APOE ɛ4 carriers and a negative relationship 12 
between AD-PRS and gmCBF. We further found regional reductions in gmCBF in 13 
individuals with higher AD-PRS across the frontal cortex (PFWE < 0.05). Our findings 14 
suggest that a larger burden of AD common genetic risk alleles is associated with 15 
attenuated cerebrovascular function, during young adulthood. These results suggest 16 
that cerebral vasculature is a mechanism by which AD risk alleles confer 17 
susceptibility.   18 
Chandler et al.                   
 3
Genome-wide association studies (GWAS) have demonstrated that 1 
Alzheimer’s disease (AD) has a highly polygenic basis, where potentially thousands 2 
of common risk alleles confer susceptibility 1. Although the polygenic architecture has 3 
shown utility in predicting AD 2,3, the neurobiological mechanisms by which these loci 4 
confer risk remain poorly understood. Imaging genetics can reveal the 5 
neurobiological mechanisms by which genetic loci confer risk for AD. For example, 6 
several studies show that common variation in the APOE, CLU, PICALM and BIN1 7 
genes are associated with AD may influence the structure and function of the human 8 
brain decades before disease onset 4-10. Although these AD risk alleles are 9 
associated with changes in brain volume and blood oxygen level dependent (BOLD) 10 
11, little is known about how they are linked to global cerebrovascular function in 11 
young asymptomatic individuals. 12 
 Cerebrovascular function has been linked to key AD biological pathways such 13 
as i) cholesterol metabolism and blood brain barrier permeability 12,13 and ii) 14 
arteriosclerosis of vessels 14. Pivotally, recent evidence suggests that vascular 15 
dysregulation is the earliest marker of AD progression, in a cohort of 40-70 year old 16 
individuals 15. In addition, several initial studies have demonstrated that the presence 17 
of AD risk alleles such as APOE ε4 or familial risk of AD are associated with 18 
alterations in neurovasculature, where older individuals with risk for developing AD 19 
show reduced cerebral blood flow (CBF) 16-19. However, no study has yet explored 20 
how the comprehensive polygenetic architecture of AD is linked to cerebrovascular 21 
function in young asymptomatic individuals. The observations from such a study 22 
could identify links between genetic risk loci that may disrupt cerebrovascular health 23 
later in life as a mechanism of increased AD susceptibility.  24 
 In the current study, we sought to extend the findings of recent evidence 25 
examining vascular dysregulation as one of the earliest markers of disease 26 
progression in AD 15 by examining vascular effects in young individuals who have 27 
increased AD genetic risk. Specifically, we sought to explore the cumulative effects 28 
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of both APOE and all the other common genetic risk loci (as measured using an AD-1 
PRS) identified by recent GWAS 1. We had two key hypotheses. First, given that 2 
reductions in grey matter CBF (gmCBF) have been observed in older individuals who 3 
possess at least one copy of the ɛ4 allele, we predict this effect would also be 4 
observed in young ɛ4 carriers. Second, we anticipated that as cumulative risk for 5 
developing AD increased, we would also observe a decrease in gmCBF. Moreover, 6 
we suggest that the alterations in gmCBF observed in AD populations 15 may be 7 
partly influenced by common genetic AD risk factors. We anticipate that the 8 
combined effect of these risk alleles can be observed in asymptomatic individuals.   9 
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Results 1 
Demographic analysis 2 
Consistent with prior epidemiological reports 20, females had higher resting gmCBF 3 
than males (Table 1).  There were no significant associations between AD-PRS and 4 
age (P >.09, in all cases) or gender (P > 0.1, in all cases). Grey matter CBF, GMV 5 
and AD-PRS were normally distributed (Shapiro test; P > 0.1 in all cases). APOE ɛ4 6 
status was not related to GMV, composite cognition or any of the seven cognitive 7 
subdomain measures (P > 0.1, in all cases; see Table 2). Similarly, AD-PRS was 8 
also not related to GMV or any cognitive measures (P > 0.1, in all cases).  9 
 10 
Genetic analysis of whole brain gmCBF 11 
The linear regression revealed a significant association between gmCBF and both 12 
APOE (β = -0.213, P = 0.044) and AD-PRS (β= -0.232, P = 0.031) controlling for 13 
age, gender and GMV (see Table 1 for full regression model; Figure 1a-b for effect 14 
size estimates). To control for population stratification effects, we repeated the 15 
regression, including the first five principle components (PCAs) from the LD-pruned 16 
genotype data. Including these additional five covariates did not significantly affect 17 
the association between gmCBF and AD-PRS (β = -0.251, P = 0.022). A SNP-wise 18 
post-hoc analysis of AD-PRS showed that the majority of alleles over-represented in 19 
the AD population (risk alleles) were associated with reduced gmCBF, while alleles 20 
over-represented in the healthy population (protective alleles) were mostly 21 
associated with increased gmCBF (Figure 1c). This assumption was confirmed via a 22 
sign test (13/17 SNPs with expected direction, P < 0.05). Consistent with an additive 23 
polygenic model, no single SNP appeared to drive the AD-PRS effects. Post-hoc 24 
analysis of AD-PRS with progressively liberal thresholds demonstrated similar 25 
relationships at PT < 5 × 10 -6 (β=-0.22, P = 0.045) but not at PT < 5 × 10 -4 (β=-0.03, 26 
P = 0.74) and PT < 5 × 10 -2 (β=0.01, P = 0.91).   27 
 28 
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Genetic analysis of grey matter density 1 
We found no other evidence of association between APOE status or AD-PRS and 2 
grey matter density in a voxel-based search across the brain (PFWE > 0.1, in all 3 
cases).    4 
 5 
Post-hoc exploratory regional analysis 6 
We conducted a post-hoc exploratory voxel-wide analysis across gmCBF. All voxel-7 
based analyses were estimated accounting for both APOE and AD-PRS (including 8 
aforementioned covariates). APOE ε4 status was not regionally associated with CBF 9 
in any voxels after correction for multiple comparisons (PFWE > 0.05). However, AD-10 
PRS was significantly associated with gmCBF in several prefrontal regions, which 11 
were significant after controlling for multiple comparisons (PFWE < 0.05). All clusters 12 
were located in the frontal lobe (including the frontal pole, middle frontal gyrus, 13 
inferior frontal gyrus, insular, frontal medial cortex & orbitofrontal cortex; see Figure 14 
2).   15 
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Discussion 1 
We find negative associations between i) APOE ε4 status and ii) AD-PRS 2 
with gmCBF, providing evidence that an increasing number common AD genetic risk 3 
loci is associated with reduction in resting gmCBF in young asymptomatic 4 
individuals. These findings support observations between APOE and reductions in 5 
resting gmCBF in older individuals 21. We also provide novel evidence that the 6 
GWAS significant common AD risk loci identified via GWAS were negatively 7 
associated with gmCBF. Our post-hoc observations between AD-PRS in frontal 8 
regions conforms with preclinical models demonstrating that reduced frontal gmCBF 9 
is linked to genetic risk 22, and may aid in the understanding of future cognitive 10 
decline 23. Together, these analyses provide support for a broader hypothesis that 11 
AD genetic risk loci may confer susceptibility via alterations in cerebrovascular 12 
health, decades before the onset of clinical symptoms. This is also evidenced by 13 
several AD-PRS imaging studies showing associations between an AD-PRS and 14 
MRI based measures of brain health, including macrostructure, white matter 15 
microstructure and blood oxygen level dependency (BOLD) during memory 16 
processing in the medial temporal lobe 24-28. 17 
These findings conform to pre-clinical models of AD where functional 18 
impairments such as widespread alterations in cerebral blood flow precede grey 19 
matter atrophy and / or cognitive impairments15. Our findings can also be assessed in 20 
light of other recent evidence showing that reduced CBF is associated with a 21 
reduction in cognitive function in older individuals 20. In the current study, we find 22 
reduced gmCBF in young asymptomatic individuals suggesting that vascular 23 
alterations are present prior to the onset of symptoms, supporting recent research 24 
conducted in an older sample 15. However, putative dynamic relationships between 25 
AD-PRS and brain imaging traits linked to AD across the lifespan remain largely 26 
untested. Furthermore, it is critical that future research investigates the precise 27 
nature of this alteration and assesses the relationship between gmCBF and oxygen 28 
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dynamics including cerebral metabolic rate of oxygen (CMRO2), oxygen extraction 1 
fraction (OEF) and oxygen diffusivity (for methods see 29-32). 2 
Our findings should be taken with the following considerations. We appreciate 3 
that while this is a large imaging sample, it is relatively small for a genetic study and 4 
further investigations should aim to a) replicate these observations to confirm these 5 
associations in younger individuals and b) expand population level imaging protocols 6 
to vascular measures. However, considering the moderate impact of both APOE and 7 
AD-PRS, we suggest that this study was adequately powered to detect the 8 
cumulative effect of these risk factors. Lastly, as the APOE status and AD-PRS 9 
effects were in the same direction, we suggest that cumulative genetic risk may be 10 
more broadly related to lower gmCBF. Lastly, as we did not see a relationship 11 
between AD-PRS and gmCBF at more liberal p-thresholds, suggesting the precise 12 
genetic architecture of AD that contributes to imaging measures remains unclear.  13 
Our observations highlight possible therapeutic benefits of exercise (and 14 
associated increases in CBF) for neurodegenerative disease 33. While evidence 15 
suggests that exercise may improve cerebrovascular health, the longitudinal effects 16 
of exercise as a therapeutic tool for AD remain unknown. Furthermore, dietary 17 
supplements such as nitrates have been shown to increase CBF in healthy adults 34. 18 
Thus, future research should investigate the beneficial effects of such a supplement 19 
for increasing gmCBF in individuals with high genetic risk of developing AD. 20 
In conclusion, we observed an association between reduced CBF and AD 21 
genetic risk loci (specifically – evidence for the involvement of APOE and 22 
independent top GWAS risk loci). Future studies may be able to investigate 23 
biologically informed pathways to understand how AD imaging phenotypes are 24 
influenced by genetic risk. We suggest that CBF may be a useful tool in 25 
understanding how genetic risk for AD may affect the human brain in young 26 
individuals and has implications for functional MRI studies that relate BOLD and 27 
models of neurovascular coupling. 28 




One hundred healthy, right-handed individuals were recruited via advertisement from 3 
Cardiff University. Participants reported no history of psychiatric or neurological 4 
illness, and were not taking any psychotropic medication. The study was approved 5 
by the ethics committee of the School of Psychology, Cardiff University. Each 6 
participant provided written informed consent. Participants were excluded from the 7 
study if they were over 35 (n=2), failed genotyping quality control (n=12) or failed 8 
quality control for the imaging procedure (n=9). In addition, those who possessed the 9 
APOE ε2ε4 isoform (n=2) were also excluded due to the presence of the protective 10 
ε2 allele, as previously described 27. Our final sample consisted of 75 individuals, 54 11 
of whom possessed no copy of the ε4 allele (pooled: ε2ε3 & ε3ε3) and 21 individuals 12 
who possessed at least one copy of the ε4 allele (pooled: ε3ε4 & ε4ε4). There was 13 
no association between APOE status with age, gender, grey matter volume (GMV) or 14 
AD-PRS (Table 1). APOE status and AD-PRS were entered into the regression 15 
model together (see statistical analysis for further details). 16 
 17 
Genotyping and extraction of DNA 18 
Genomic DNA was obtained from saliva using Oragene OG-500 saliva kits (DNA 19 
Genotek, Inc., Ontario, Canada). Genotyping was performed using custom Illumina. 20 
HumanCoreExome-24 BeadChip genotyping arrays, which contain approximately 21 
500,000 common genetic variants (Illumina, Inc., San Diego, CA). Quality control and 22 
imputation were implemented in plink 1.9 35. Briefly, individuals were excluded for any 23 
of the following reasons: 1) ambiguous sex (where samples with undetermined X 24 
chromosome heterozygosity were excluded); 2) cryptic relatedness up to third-25 
degree relatives as ascertained using identity by descent; 3) genotyping 26 
completeness less than 98%; 4) non-European ethnicity admixture which was 27 
determined via population stratification, where samples that clustered outside the 28 
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CEU HapMap3 population using principal component analysis were excluded); and 1 
5) outliers from an autosomal heterozygosity filter. Single nucleotide polymorphisms 2 
(SNPs) were excluded where the minor allele frequency was less than 1%, if the call 3 
rate was less than 98%, or if the χ2 test for Hardy-Weinberg equilibrium had a p 4 
value less than 1e-6. A total of 233054 genotyped SNPs remained after quality 5 
control. Autosomal chromosomes were imputed using the reference panel HRCv1.1 6 
(hrc.r1.1.2016) using a mixed population panel 36. Phasing was completed using 7 
Eagle v2.3 37 and imputation was performed using Mimimac3 38. Imputed data was 8 
converted to best-guess genotypes 35 with multi-allelic sites removed. SNP filters for 9 
HWE (1e-6) and minor allele frequency (1%) were re-applied. SNP ids were updated 10 
from chr:bp to rsIDs using dbsnp_138.b37.vcf. A total of 7545595 imputed SNPs for 11 
consideration in AD-PRS analysis.  12 
 13 
Creation of polygenic scores 14 
Polygenic score calculations were performed according to the procedure described 15 
by the International Schizophrenia Consortium 39. Training data were from the most 16 
recent AD GWAS 1. These data are publicly available from http://www.pasteur-17 
lille.fr/en/recherche/u744/igap/igap_download.php. SNPs were removed from all 18 
analyses if they had a low minor allele frequency (P < 0.01). Subsequently, the data 19 
were pruned for linkage disequilibrium using the clumping function (--clump) in plink 20 
1.9 35 removing SNPs within 500 kilobase (--clump-kb) and R2 > 0.25 (--clump-r2) 21 
with a more significantly associated SNP. We used the --score command in PLINK to 22 
calculate polygenic score. For the creation of the AD-PRS, we considered SNPs that 23 
were associated with AD that surpassed the GWAS threshold (PT < 5 × 10 -8). We 24 
chose a conservative P-threshold as prior fMRI neuroimaging studies have 25 
demonstrated that conservative P-thresholds have been successful in predicting 26 
blood oxygenation level dependent (BOLD) MRI measures linked to AD 28.  As we 27 
aimed to understand the contribution of SNPs outside the APOE locus, we employed 28 
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a conservative approach, where we removed all SNPs from chromosome 19 before 1 
creating an AD-PRS. We aimed to remove any confounding signal from variants in 2 
linkage disequilibrium (LD) with the APOE locus. A total of 17 SNPs were considered 3 
in the AD-PRS calculation. Removing the entire APOE locus (removing chr19: 4 
45.053-45.73Mb, rather than the whole of chromosome 19; NSNPS = 19) did not 5 
significantly affect our results. We further created 3 additional AD-PRS at 6 
progressively liberal P-thresholds to explore optimal model performance (PT < 5 × 10 7 
-6; PT < 5 × 10 -4; PT < 5 × 10 -2). . Although our sample predominately included 8 
individuals of western European descent, we also aimed to ensure that the 9 
population stratification was not accounting for variation linked to AD-PRS. We 10 
therefore extracted the first five principle components from the linkage-disequilibrium 11 
(LD) pruned genotypes and included these as covariates in the analysis.  12 
 13 
Imaging procedure 14 
Imaging data were collected on a 3 Tesla General Electric (GE) scanner. Anatomical 15 
T1-weighted images were acquired with a 3D fast spoiled gradient echo sequence 16 
(FSPGR) (parameters: 172 contiguous sagittal slices with a slice thickness of 1mm, 17 
TR = 7.9, TE = 3ms, inversion time of 450ms, flip angle = 20°, a FOV of 18 
256 × 256 × 176 mm, matrix size 256 × 256 × 192 to yield 1 mm isotropic voxel 19 
resolution images).  20 
Resting CBF data was collected using a pseudo-continuous arterial spin labelling 21 
(PCASL) sequence 40. The study consisted of a single MRI session (which also 22 
comprised other functional and structural scans), and the PCASL sequence lasted 23 
approximately 6 minutes. Resting-state CBF maps (rCBF) and whole brain CBF 24 
(wbCBF) measurements were created with a PCASL sequence identical to the one 25 
previously described.  Parameters included a 1.5 second tag and a post-labelling 26 
delay of 1.5 seconds. The images for the PCASL sequence were acquired using a 27 
3D fast spin echo (FSE) spiral multi-slice readout (parameters:  number of excitations 28 
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= 3, time to echo = 32ms, echo time train length = 64, TR = 5.5 seconds, matrix size 1 
= 48 x 64 x 60, FOV = 18 x 23 x 18 cm). 2 
 3 
Grey matter CBF (gmCBF) analysis 4 
Recent evidence suggests vascular dysfunction in AD is uniformly reduced across 5 
the brain 15, therefore we looked at whether this is also the case in young individuals 6 
with increased cumulative risk for developing AD. This was conducted by extracting 7 
mean CBF from each grey matter image. 8 
Briefly, grey matter CBF was measured in native space for each of the 75 9 
individuals. First, anatomical T1 weighted FSPGR images were registered to the M0 10 
image acquired as part of the calibration of the CBF image acquisition, generating a 11 
transformation matrix. This transformation matrix was then applied to the skull 12 
stripped T1w anatomical (with reference/warping to the M0) using FSL’s Brain 13 
Extraction Tool 41. From here, we used linear registration FSL’s FLIRT 42,43 to register 14 
the skull stripped anatomical image to the M0 transformation matrix (Montreal 15 
Neurological Institute (MNI) space) and the difference was calculated between this 16 
and the subjects native space, providing data in the same space as the CBF data. 17 
The two transformation matrices for each participant were then concatenated to 18 
produce a matrix for the low resolution CBF image. All CBF images were then 19 
warped to standard MNI template using FSL’s FLIRT 41,42. The priors for the grey 20 
matter were then registered to the skull stripped M0 image, creating a mask of each 21 
individual’s grey matter where CBF values could be extracted. Grey matter volume 22 
(GMV) was approximated as the mean intensity of the segmented grey matter image. 23 
See Figure 3 for a) the mean gmCBF of the cohort and b) for APOE ɛ4- and c) APOE 24 
ɛ4+.    25 
 26 
Voxel Based Morphometry 27 
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Regional grey matter density was estimated for each individual. Briefly, structural 1 
data was analysed with FSL-VBM (44, http://fsl.fmrib.ox.ac.uk/fsl/fslwiki/FSLVBM), an 2 
optimised VBM protocol 45 carried out with FSL tools 42. First, structural images were 3 
brain-extracted and grey matter-segmented before being registered to the MNI 152 4 
standard space using non-linear registration. The resulting images were averaged 5 
and flipped along the x-axis to create a left-right symmetric, study-specific grey 6 
matter template. Second, all native grey matter images were non-linearly registered 7 
to this study-specific template and "modulated" to correct for local expansion (or 8 
contraction) due to the non-linear component of the spatial transformation. The 9 
modulated grey matter images were then smoothed with an isotropic Gaussian 10 
kernel with a sigma of 3mm. These images were entered into same regression 11 
models as the standardised gmCBF images.  12 
 13 
Power analysis 14 
Current estimates suggest that the combination of APOE locus and GWAS loci 15 
(NSNPS=20) classify AD cases and controls with an accuracy of 66%, assuming a 16 
lifetime prevalence of 2% 2, equating to a moderate effect size (Cohen’s D = 0.583; r 17 
= 0.28) 46. Based upon this anticipated effect size, we had approximately 69% power 18 
to detect an combined effect of these AD risk loci (N=75, α = 0.05), calculated with 19 
‘pwr’ in R 47.  20 
 21 
Cognitive instruments 22 
We assessed cognition via the MATRICS Consensus Cognitive Battery (MCCB), 23 
which measures composite cognition across seven sub-domains including working 24 
memory, attention, speed of processing, verbal and visual learning and social 25 
cognition 48.     26 
 27 
Statistical analysis 28 
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Linear regression models were employed in R (https://www.r-project.org/; version 1 
3.1.3) to assess the impact of both APOE and AD-PRS risk on whole brain grey 2 
matter CBF. Whole brain grey matter CBF was introduced as our dependent variable 3 
where APOE and AD-PRS were added together as regressors. Age, gender and 4 
grey matter volume (GMV) were included as covariates in the analyses. A post-hoc 5 
analysis was repeated using the aforementioned linear regression approach (using 6 
the same covariates) and was conducted at a voxel-wise level to explore regional 7 
effects of APOE and AD-PRS on gmCBF. For whole brain analysis (gmCBF and 8 
GMV),  the family-wise error rate was controlled with nonparametric permutation 9 
testing (5000 permutations) and TFCE (threshold free cluster enhancement) which 10 
effectively controls for multiple comparisons, compared to cluster extent thresholding 11 
49.  12 
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Approval and accordance 1 
The study was approved by the ethics committee of the School of Psychology, 2 
Cardiff University. Methods were carried out in accordance with guidelines and 3 
regulations. 4 
 5 
Informed consent 6 
Informed consent was obtained for all procedures used for this study. 7 
 8 
Data availability 9 
Analysis code and data can be made available upon request to Cardiff University 10 
Brain Research Imaging Centre. 11 
  12 
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Table 1. Statistics for each predictor in the model 1 
Predictor  Standardized Estimate Standard Error t-value P value 
AD-PRS -0.232 0.751 -2.201 0.031 
APOE (ɛ4) -0.213 1.633 -2.055 0.044 
Age -0.085 0.259 -0.737 0.464 
Gender (Male) -0.356 1.708 -3.046 0.003 
GMV 0.032 0.899 0.250 0.803 
 2 
Table 1 Legend. Linear regression model of whole grey matter CBF. Estimate = 3 
adjusted beta coefficients. GMV = grey matter volume, AD-PRS = Alzheimer’s 4 
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Table 2.  1 
 APOE ɛ4 (-) n=54 APOE ɛ4 (+) n=21 P 
Gender M=19 / F = 35 M=9 / F = 12  X2 = 0.12 0.726 
 Mean SD Mean SD  
Age 23.759 3.192 23.952 3.170 0.814 
GMV 0.767 0.011 0.768 0.011 0.719 
AD-PRS -0.075 0.935 0.192 1.154 0.351 
SoP 68.764 23.639 76.042 19.612 0.185 
AV 44.214 26.689 51.118 22.990 0.276 
WM 56.411 21.998 58.161 23.945 0.775 
VrblLrng 51.480 28.071 47.137 29.272 0.566 
VisLrng 66.795 25.647 62.667 27.922 0.563 
RPS 54.906 28.815 62.205 24.900 0.287 
SC 45.295 25.777 47.147 30.897 0.810 
Comp 59.971 23.479 63.183 18.739 0.543 
Table 2 Legend. Descriptive / demographic statistics for individuals included in final 2 
linear regression models (n=75). X2 = chi squared test for gender. All other 3 
demographics were tested via two-sample t-test. SD = standard deviation. GMV = 4 
grey matter volume; AD-PRS = Alzheimer’s disease polygenic risk score (z-scores). 5 
SoP = Speed of Processing; AV = Attention Vigilance; WM = Working Memory; 6 
VrblLrng = Verbal Learning; VisLrng = Visual Learning; RPS = Reasoning and 7 
Problem Solving; SC = Social Cognition; Comp = Composite Cognition Score.   8 
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 1 
Figure 1. Results for both the APOE status group difference in gmCBF and the 2 
association between AD-PRS and gmCBF. 3 
(a) Total gmCBF (grey matter cerebral blood flow) stratified by presence of APOE ε4 4 
isoform; (b) association between gmCBF and AD-PRS. R2 and p-values estimated 5 
from linear regression, controlling for age, gender, GMV and PRS (in (a)) or APOE 6 
(in (b)). (c). Reflects the individual contributions to gmCBF for all SNPs within the 7 
AD-PRS (NSNPS=17), controlling for covariates. CIs = confidence intervals. 8 
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 1 
Figure 2. Voxel wide analysis of gmCBF for AD-PRS. 2 
Regional association between gmCBF and AD-PRS across all grey matter. All clusters that 3 
remain (red-yellow) reflect voxels that survived correction across the whole brain (using 4 
threshold free cluster enhancement) with permutation testing (N=5000) (PFWE< 0.05). Color-5 
bar represents regional t-statistic.  6 
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 1 
Figure 3. Average gmCBF maps. 2 
Top. A mean gmCBF map of all participants within the sample (N=75). Middle. Mean gmCBF 3 
for APOE ɛ4- group (N=54). Below. Mean gmCBF for APOE ɛ4+ group (N=21). Colorbar 4 
represents regional gmCBF (ml/min/100g).  5 
 6 



